ArticleCureus2025
Paraneoplastic Cerebellar Syndrome Revealing Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Movement Disorders Associated With Breast Cancer: A Systematic Review.Annals of Indian Academy of Neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paraneoplastic cerebellar degeneration (PCD) is a rare neurological disorder that can precede the diagnosis of an underlying malignancy by several months or even years. We report the case of a 46-year-old woman who presented with progressive gait instability, dysarthria, and nystagmus. Brain magnetic resonance imaging (MRI) revealed cerebellar atrophy without any mass lesion, and serologic testing showed strong anti-Yo antibody positivity. Two years later, she was diagnosed with a human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor-negative invasive ductal carcinoma of the breast. The patient underwent a modified radical mastectomy followed by adjuvant chemotherapy and trastuzumab. Despite appropriate oncologic treatment, her neurological symptoms persisted and gradually worsened. This case highlights the diagnostic challenge of PCD, particularly when neurological manifestations precede tumor detection, and suggests that HER2-positive breast cancer may also be associated with anti-Yo antibodies. Early recognition of this syndrome and systematic malignancy screening are essential to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.